NOW ENROLLING PHASE III sunRIZE TRIAL
In the study of congenital hyperinsulinism
Learn More »
Investors & Media
Overview
Corporate Presentation
News
Events
Stock Quote and Chart
Historical Data
Analyst Coverage
SEC Filings
Governance
Info
Contact Us
Therapeutic Focus
Pipeline
RZ358
RZ402
Publications
Data Presentations
For Patients
Overview
Living with HI
Living with DME
About
Our Mission
Leadership
Board of Directors
Scientific Advisory Board
Join Us
Our Mission
Open Positions
Benefits
Contact Us
Investors & Media
Overview
Corporate Presentation
News
Events
Stock Quote and Chart
Historical Data
Analyst Coverage
SEC Filings
Governance
Info
Investors & Media
|
Overview
|
Corporate Presentation
|
News
|
Events
|
Stock Quote and Chart
|
Historical Data
|
Analyst Coverage
|
SEC Filings
|
Governance
|
Info
|
Contact Us
|
Rezolute Preps for Phase III with Rare, Pediatric Disorder Drug
Back to Careers
MENU
Therapeutic Focus
Pipeline
RZ358
RZ402
Publications
Data Presentations
For Patients
Overview
Living with HI
Living with DME
About
Our Mission
Leadership
Board of Directors
Scientific Advisory Board
Join Us
Our Mission
Open Positions
Benefits
Contact Us
Investors & Media
Overview
Corporate Presentation
News
Events
Stock Quote and Chart
Historical Data
Analyst Coverage
SEC Filings
Governance
Info
